Lisata Therapeutics Stock Investor Sentiment

LSTA Stock  USD 2.76  0.06  2.13%   
About 61% of Lisata Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Lisata Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
a minute ago at businesswire.com         
Vernal Biosciences Appoints Jim Petrilla as CEO Board Director
businesswire News
21 hours ago at insidermonkey.com         
Why Neurocrine Biosciences Is the Most Profitable Pharmaceutical Stock Right Now?
insidermonkey News
a day ago at gurufocus.com         
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635
Gurufocus Stories at Macroaxis
a day ago at thelincolnianonline.com         
Vinva Investment Management Ltd Increases Position in Neurocrine Biosciences, Inc.
news
2 days ago at thelincolnianonline.com         
Celebrus Technologies Reaches New 1-Year High Heres Why
news
2 days ago at thelincolnianonline.com         
Evelo Biosciences Target of Unusually High Options Trading
news
3 days ago at simplywall.st         
Swelling losses havent held back gains for LigaChem Biosciences shareholders since theyre up 256 per...
Simply Wall St News at Macroaxis
few days ago at seekingalpha.com         
Neurogene and Ventyx Biosciences rises after insider buying by executives
seekingalpha News
few days ago at finance.yahoo.com         
Marvel Biosciences Announces Promising New Data from Rett Syndrome Study and Plans to Discuss Orphan...
Yahoo News
few days ago at investing.com         
Aptose Biosciences CEO William Rice acquires 20,000 in shares
Investing News at Macroaxis
few days ago at globenewswire.com         
Aptose Biosciences Inc. Announces Closing of 8 Million Public Offering
Macroaxis News: globenewswire.com
few days ago at investing.com         
Enveric Biosciences faces potential Nasdaq delisting
Investing News at Macroaxis
few days ago at gurufocus.com         
Forte Biosciences to Host RD Day December 3, 2024
Gurufocus Stories at Macroaxis
few days ago at gurufocus.com         
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, ...
Gurufocus Stories at Macroaxis
six days ago at thelincolnianonline.com         
Aptose Biosciences Hits New 1-Year Low Heres What Happened
news
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.

Lisata Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Pacific Biosciences of California Advances While Market Declines Some Information for Investors
10/31/2024
2
Pacific Biosciences of California Inc Q3 2024 Earnings EPS Beats Estimates at -0. ...
11/07/2024
3
ARMISTICE CAPITAL, LLC Increases Stake in Aptose Biosciences Inc
11/15/2024
4
Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinsons Research Through Development of Next Generation Biomarker As...
11/19/2024
5
Taconic Biosciences Announces New U.S. West Coast Production Location
11/20/2024
6
Parse Biosciences Partners with OMAPiX to Expand Access to Single Cell Sequencing
11/21/2024
7
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
11/22/2024
8
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, ...
11/25/2024
9
Neurogene and Ventyx Biosciences rises after insider buying by executives
11/26/2024

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals